What antibiotics are recommended for an otherwise healthy adult with community‑acquired pneumonia being treated as an outpatient?

Antibiotic Treatment for Outpatient Community-Acquired Pneumonia in Healthy Adults

For otherwise healthy adults with community-acquired pneumonia treated as outpatients, start with a macrolide (azithromycin 500 mg daily or clarithromycin 500 mg twice daily) or doxycycline 100 mg twice daily as first-line therapy. 1

First-Line Therapy for Patients Without Comorbidities

For previously healthy adults with no risk factors for drug-resistant Streptococcus pneumoniae (DRSP), the preferred empiric regimens are:

• Macrolide monotherapy: Azithromycin 500 mg daily or clarithromycin 500 mg twice daily 1
• Doxycycline: 100 mg twice daily as an alternative 1

These narrow-spectrum options are strongly recommended because they provide excellent coverage for typical and atypical pathogens causing CAP in healthy adults, with lower rates of adverse drug events compared to broad-spectrum alternatives. 2

A 2024 comparative safety study demonstrated that macrolide monotherapy had significantly fewer adverse events than broad-spectrum regimens, including lower rates of nausea/vomiting, diarrhea, and vulvovaginal candidiasis. 2

Therapy for Patients With Comorbidities or Recent Antibiotic Use

If the patient has comorbidities (chronic heart, lung, liver, or renal disease; diabetes; alcoholism; malignancies; asplenia; immunosuppression) or has used antibiotics within the previous 3 months, escalate to:

• Respiratory fluoroquinolone monotherapy: Levofloxacin 750 mg daily or moxifloxacin 400 mg daily 1
• β-lactam plus macrolide combination: High-dose amoxicillin (1 g three times daily) or amoxicillin-clavulanate (2 g twice daily) PLUS azithromycin or clarithromycin 1
• Alternative β-lactams: Ceftriaxone, cefpodoxime, or cefuroxime 500 mg twice daily can substitute for amoxicillin 1

Important Clinical Considerations

Fluoroquinolone use should be judicious despite their excellent efficacy (highest p-scores for clinical response and mortality in network meta-analyses). 3 The 2019 ATS/IDSA guidelines acknowledge increasing FDA warnings about fluoroquinolone-associated adverse events, including tendon rupture, peripheral neuropathy, and aortic dissection. 1 Reserve fluoroquinolones for patients with comorbidities, not as routine first-line therapy in healthy adults.

Avoid repeating the same antibiotic class if the patient received antibiotics within the past 3 months, due to increased risk of bacterial resistance. 1

Regional resistance patterns matter: In areas with high rates (≥25%) of high-level macrolide-resistant S. pneumoniae (MIC ≥16 mcg/mL), consider using fluoroquinolones or β-lactam/macrolide combinations even for patients without comorbidities. 1

Treatment Duration

Treat for 3 days if clinically stable by day 3, 5 days if stable by day 5, or 7 days for other uncomplicated cases. 4, 5 Clinical stability is defined as resolution of fever, normalization of vital signs, and ability to take oral medications. Recent evidence supports shorter durations (3-7 days) as non-inferior to longer courses, reducing antibiotic exposure without compromising efficacy. 4

Common Pitfalls to Avoid

• Do not use broad-spectrum antibiotics routinely in healthy adults: This increases adverse events without improving outcomes. 2
• Do not use fluoroquinolones as first-line in previously healthy patients: Reserve for those with comorbidities or contraindications to other agents. 1
• Do not continue antibiotics beyond clinical stability: Prolonged treatment increases adverse events and resistance without benefit. 4
• Do not ignore MRSA or Pseudomonas risk factors: Though rare in outpatients, patients with these risk factors require expanded coverage (vancomycin/linezolid for MRSA; antipseudomonal β-lactams for Pseudomonas). 1